Latest & greatest articles for influenza

The Trip Database is a leading resource to help health professionals find trustworthy answers to their clinical questions. Users can access the latest research evidence and guidance to answer their clinical questions. We have a large collection of systematic reviews, clinical guidelines, regulatory guidance, clinical trials and many other forms of evidence. If you wanted the latest trusted evidence on influenza or other clinical topics then use Trip today.

This page lists the very latest high quality evidence on influenza and also the most popular articles. Popularity measured by the number of times the articles have been clicked on by fellow users in the last twelve months.

What is Trip?

Trip is a clinical search engine designed to allow users to quickly and easily find and use high-quality research evidence to support their practice and/or care.

Trip has been online since 1997 and in that time has developed into the internet’s premier source of evidence-based content. Our motto is ‘Find evidence fast’ and this is something we aim to deliver for every single search.

As well as research evidence we also allow clinicians to search across other content types including images, videos, patient information leaflets, educational courses and news.

For further information on Trip click on any of the questions/sections on the left-hand side of this page. But if you still have questions please contact us via jon.brassey@tripdatabase.com

Top results for influenza

21. Immunogenicity and safety of subunit influenza vaccines in pregnant women

Immunogenicity and safety of subunit influenza vaccines in pregnant women 29637079 2018 11 14 2312-0541 4 2 2018 Apr ERJ open research ERJ Open Res Immunogenicity and safety of subunit influenza vaccines in pregnant women. 00060-2017 10.1183/23120541.00060-2017 Pregnancy is a condition of modulated immune suppression, so this group of patients has increased risk of infectious diseases. Trivalent subunit vaccines, unadjusted Agrippal S1 (group I) and immunoadjuvant Grippol Plus (group II (...) ), containing 5 μg of actual influenza virus strains, were administered respectively to 37 and 42 women in the second and third trimester of physiological pregnancy. The administration of subunit influenza vaccines was accompanied by the development of local reactions in no more than 10% of patients, compared with 4.9% of the 41 pregnant women in the placebo group (group III). Systemic reactions were of a general somatic nature, did not differ between vaccinated and placebo groups, and were not associated

ERJ open research2018 Full Text: Link to full Text with Trip Pro

22. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial

Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial 29572291 2018 03 24 1468-2060 2018 Mar 23 Annals of the rheumatic diseases Ann. Rheum. Dis. Impact of temporary methotrexate discontinuation for 2 weeks on immunogenicity of seasonal influenza vaccination in patients with rheumatoid arthritis: a randomised clinical trial. annrheumdis-2018-213222 10.1136/annrheumdis (...) -2018-213222 To determine whether a 2-week methotrexate (MTX) discontinuation after vaccination improves the efficacy of seasonal influenza vaccination in patients with rheumatoid arthritis (RA). In this prospective randomised parallel-group multicentre study, patients with RA on stable dose of MTX were randomly assigned at a ratio of 1:1 to continue MTX or to hold MTX for 2 weeks after 2016-2017 quadrivalent seasonal influenza vaccine containing H1N1, H3N2, B-Yamagata and B-Victoria. The primary

EvidenceUpdates2018

23. Influenza epidemiological information prepared for WHO informal meeting on strain composition for inactivated influenza vaccines for use in season 2018-19 Geneva, Feb 2018

Influenza epidemiological information prepared for WHO informal meeting on strain composition for inactivated influenza vaccines for use in season 2018-19 Geneva, Feb 2018 Influenza epidemiological information prepared for WHO informal meeting on strain composition for inactivated influenza vaccines for use in season 2018-19 - NIPH Selected items added to basket Close Vis søkefelt How can we help you today? Search for: Søk Menu • Influenza epidemiological information prepared for WHO informal (...) meeting on strain composition for inactivated influenza vaccines for use in season 2018-19 Søk i Folkehelsa.no Search for: Søk Infectious diseases & Vaccines Close Mental & Physical health Close Environment & Lifestyle Close Health in Norway Close Quality & Knowledge Close Research & Access to data Close Summary In February/March, the WHO annually assesses if the components of the influenza vaccine for the northern hemisphere for the coming season should be changed or not. The WHO National Influenza

Norwegian Institute of Public Health2018

24. Vaccine recommendations for children and youth for the 2017/2018 influenza season

Vaccine recommendations for children and youth for the 2017/2018 influenza season The Canadian Paediatric Society continues to encourage annual influenza vaccination for ALL children and youth ≥6 months of age. Recommendations from the National Advisory Committee on Immunization (NACI) for the 2017/2018 influenza season are not substantially changed from those of last season. NACI has conducted a review of all available vaccine effectiveness data concerning live attenuated influenza vaccine (...) (LAIV) and concludes that current evidence supports the continued use of LAIV in Canada, although use is not currently recommended in the USA because of concern about efficacy. Key Words:  Children; Influenza vaccine; Inactivated influenza vaccine; LAIV; NACI

Canadian Paediatric Society2018

25. Influenza news from the frontline: what's happening?

Influenza news from the frontline: what's happening? Influenza news from the frontline: what’s happening? Anita K. Simonds Royal Brompton and Harefield NHS Foundation Trust, London, UK. Correspondence: Anita K. Simonds, Royal Brompton and Harefield NHS Foundation Trust, London SW3 6NP, UK. E-mail: A.Simonds@rbht.nhs.uk @ERSpublications Chief Editor Anita Simonds explains what’s happening on the frontline of the flu season http://ow.ly/fBW630iiYC5 Cite this article as: Simonds AK. Influenza news (...) from the frontline: what’s happening? ERJ Open Res 2018; 4: 00020-2018 [https://doi.org/10.1183/23120541.00020-2018]. Three times more people dying from flu in UK than last winter The Guardian; January 25, 2018 [1] Flu patients arrive in droves, and a hospital rolls out the “Surge tent” The New York Times; February 2, 2018 [2] French health chiefs on alert as Paris region hit by flu epidemic The Local; December 14, 2017 [3] Flu epidemic rages in Japan with record-high cases in one week reported

ERJ open research2018 Full Text: Link to full Text with Trip Pro

26. Acute macular neuroretinopathy associated with influenza vaccination with decreased flow at the deep capillary plexus on OCT angiography

Acute macular neuroretinopathy associated with influenza vaccination with decreased flow at the deep capillary plexus on OCT angiography Redirecting

American journal of ophthalmology case reports2018 Full Text: Link to full Text with Trip Pro

27. The Cost of Interventions to Increase Influenza Vaccination: A Systematic Review

The Cost of Interventions to Increase Influenza Vaccination: A Systematic Review 29362167 2018 01 30 1873-2607 54 2 2018 Feb American journal of preventive medicine Am J Prev Med The Cost of Interventions to Increase Influenza Vaccination: A Systematic Review. 299-315 S0749-3797(17)30698-0 10.1016/j.amepre.2017.11.010 Influenza vaccination rates remain below Healthy People 2020 goals. This project sought to systematically review economic evaluations of healthcare-based quality improvement (...) interventions for improving influenza vaccination uptake among general populations and healthcare workers. The databases MEDLINE, Econlit, Centre for Reviews & Dissemination, Greylit, and Worldcat were searched in July 2016 for papers published from January 2004 to July 2016. Eligible studies evaluated efforts by bodies within the healthcare system to encourage influenza vaccination by means of an organizational or structural change. For each study, program costs per enrollee and per additional enrollee

EvidenceUpdates2018

28. Influenza vaccines in immunosuppressed adults with cancer.

Influenza vaccines in immunosuppressed adults with cancer. BACKGROUND: This is an update of the Cochrane review published in 2013, Issue 10.Immunosuppressed cancer patients are at increased risk of serious influenza-related complications. Guidelines, therefore, recommend influenza vaccination for these patients. However, data on vaccine effectiveness in this population are lacking, and the value of vaccination in this population remains unclear. OBJECTIVES: To assess the effectiveness (...) of influenza vaccine in immunosuppressed adults with malignancies. The primary review outcome is all-cause mortality, preferably at the end of the influenza season. Influenza-like illness (ILI, a clinical definition), confirmed influenza, pneumonia, any hospitalisations, influenza-related mortality and immunogenicity were defined as secondary outcomes. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase and LILACS databases up to May 2017. We searched

Cochrane2018

29. Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection.

Acute Myocardial Infarction after Laboratory-Confirmed Influenza Infection. BACKGROUND: Acute myocardial infarction can be triggered by acute respiratory infections. Previous studies have suggested an association between influenza and acute myocardial infarction, but those studies used nonspecific measures of influenza infection or study designs that were susceptible to bias. We evaluated the association between laboratory-confirmed influenza infection and acute myocardial infarction. METHODS (...) : We used the self-controlled case-series design to evaluate the association between laboratory-confirmed influenza infection and hospitalization for acute myocardial infarction. We used various high-specificity laboratory methods to confirm influenza infection in respiratory specimens, and we ascertained hospitalization for acute myocardial infarction from administrative data. We defined the "risk interval" as the first 7 days after respiratory specimen collection and the "control interval" as 1

NEJM2018

30. Accuracy and Discomfort of Different Types of Intranasal Specimen Collection Methods for Molecular Influenza Testing in Emergency Department Patients

Accuracy and Discomfort of Different Types of Intranasal Specimen Collection Methods for Molecular Influenza Testing in Emergency Department Patients 29174837 2017 11 27 1097-6760 2017 Nov 23 Annals of emergency medicine Ann Emerg Med Accuracy and Discomfort of Different Types of Intranasal Specimen Collection Methods for Molecular Influenza Testing in Emergency Department Patients. S0196-0644(17)31659-1 10.1016/j.annemergmed.2017.09.010 While development is under way of accurate, point-of-care (...) molecular tests for influenza infection, the optimal specimen type for molecular tests remains unclear. Compared with standard nasopharyngeal swab specimens, less invasive nasal swab and midturbinate swab specimens may cause less patient discomfort and be more suitable for routine emergency department (ED) testing, although possibly at the expense of diagnostic accuracy. We compare both the accuracy of a polymerase chain reaction molecular influenza test and discomfort between these 3 intranasal

EvidenceUpdates2018

31. Early risk assessment: What to expect of the 2017/18 influenza season in Norway

Early risk assessment: What to expect of the 2017/18 influenza season in Norway What to expect of the 2017/18 influenza season in Norway - NIPH Selected items added to basket Close Vis søkefelt How can we help you today? Search for: Søk Menu • • What to expect of the 2017/18 influenza season in Norway Søk i Folkehelsa.no Search for: Søk Infectious diseases & Vaccines Close Mental & Physical health Close Environment & Lifestyle Close Health in Norway Close Quality & Knowledge Close Research (...) & Access to data Close The report is based on data from a late-summer serosurvey, early-season surveillance data, vaccine sales and experience from previous influenza seasons. The report is meant to support capacity planning in the health services, provide background information to infection control and other health-care and public health personnel, as well as to provide in-depth information on influenza outbreaks in general. At this point, as the 2017-2018 outbreak is beginning to unfold

Norwegian Institute of Public Health2018

32. Avian influenza A (H7N9) virus infection

Avian influenza A (H7N9) virus infection Avian influenza A (H7N9) virus infection - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Avian influenza A (H7N9) virus infection Last reviewed: August 2018 Last updated: June 2018 Summary The epidemic has been geographically focused in China, and is associated with exposure to infected poultry. The risk to public health is low; however, the pandemic potential of this virus (...) of respiratory tract samples is the recommended diagnostic test. Treatment involves supportive care, specialised intensive-care management, and administration of a neuraminidase inhibitor. Definition Avian influenza A viruses are generally confined to birds but have infected other mammals and some viruses have crossed the species barrier to sporadically infect humans. Highly pathogenic avian influenza (HPAI) A(H5N1) virus is capable of causing severe multi-system disease in birds, humans, and other mammals

BMJ Best Practice2018

33. Influenza infection

Influenza infection Influenza infection - Symptoms, diagnosis and treatment | BMJ Best Practice You'll need a subscription to access all of BMJ Best Practice Search  Influenza infection Last reviewed: August 2018 Last updated: June 2018 Summary Characterised by upper and lower respiratory tract symptoms of rhinorrhoea, cough, fever, chills, headache, and myalgia. Typically presents in winter season. Can occur in local community outbreaks, epidemics, and, rarely, pandemics. Vaccination (...) for prevention is available. Definition Acute respiratory tract infection typically caused by seasonal influenza A or B virus. The virus is transmitted by inhalation of infected respiratory secretions that have been aerosolised through coughing, sneezing, or talking. Brankston G, Gitterman L, Hirji Z, et al. Transmission of influenza A in human beings. Lancet Infect Dis. 2007;7:257-265. http://www.ncbi.nlm.nih.gov/pubmed/17376383?tool=bestpractice.com History and exam winter season current influenza outbreak

BMJ Best Practice2018

34. Estimates of global seasonal influenza-associated respiratory mortality: a modelling study.

Estimates of global seasonal influenza-associated respiratory mortality: a modelling study. BACKGROUND: Estimates of influenza-associated mortality are important for national and international decision making on public health priorities. Previous estimates of 250 000-500 000 annual influenza deaths are outdated. We updated the estimated number of global annual influenza-associated respiratory deaths using country-specific influenza-associated excess respiratory mortality estimates from 1999 (...) -2015. METHODS: We estimated country-specific influenza-associated respiratory excess mortality rates (EMR) for 33 countries using time series log-linear regression models with vital death records and influenza surveillance data. To extrapolate estimates to countries without data, we divided countries into three analytic divisions for three age groups (<65 years, 65-74 years, and ≥75 years) using WHO Global Health Estimate (GHE) respiratory infection mortality rates. We calculated mortality rate

Lancet2017

35. Integrative gene network analysis identifies key signatures, intrinsic networks and host factors for influenza virus A infections

Integrative gene network analysis identifies key signatures, intrinsic networks and host factors for influenza virus A infections ARTICLE OPEN Integrative gene network analysis identi?es key signatures, intrinsic networks and host factors for in?uenza virus A infections ChristianV.Forst 1 ,BinZhou 2 ,MinghuiWang 1 ,Tsui-WenChou 2 ,GuyMason 2 ,Won-minSong 1 ,EricSchadt 1 ,ElodieGhedin 2,3 and Bin Zhang 1 In?uenzaAvirus,withthelimitedcodingcapacityof10–14proteins

NPJ systems biology and applications2017 Full Text: Link to full Text with Trip Pro

36. Real-time modelling of a pandemic influenza outbreak

Real-time modelling of a pandemic influenza outbreak Real-time modelling of a pandemic influenza outbreak Journals Library An error occurred retrieving content to display, please try again. >> >> >> Page Not Found Page not found (404) Sorry - the page you requested could not be found. Please choose a page from the navigation or try a website search above to find the information you need. >> >> >> >> Issue {{metadata .Issue }} Toolkit 1)"> 0)"> {{metadata.Title}} {{metadata.Headline}} This study (...) has shown that real-time inference of pandemic flu is feasible using spatially disaggregated data and a system to implement this has been developed to fit with pandemic preparedness plans {{author}} {{($index , , , & . Paul J Birrell 1 , Richard G Pebody 2 , André Charlett 2 , Xu-Sheng Zhang 2 , Daniela De Angelis 1, 2, * 1 Medical Research Council Biostatistics Unit, Cambridge Institute of Public Health, University of Cambridge, Cambridge, UK 2 National Infections Service, Public Health England

NIHR HTA programme2017

37. Zoonotic influenza viruses: antigenic and genetic characteristics and development of candidate vaccine viruses for pandemic preparedness –Virus grippaux zoonotiques: caractéristiques génétiques et antigéniques et mise au point de virus vaccinaux candidat

Zoonotic influenza viruses: antigenic and genetic characteristics and development of candidate vaccine viruses for pandemic preparedness –Virus grippaux zoonotiques: caractéristiques génétiques et antigéniques et mise au point de virus vaccinaux candidat WHO IRIS: Zoonotic influenza viruses: antigenic and genetic characteristics and development of candidate vaccine viruses for pandemic preparedness –Virus grippaux zoonotiques: caractéristiques génétiques et antigéniques et mise au point de (...) virus vaccinaux candidats pour se préparer à une pandémie Browse Related links Files in This Item: File Description Size Format 364.67 kB Adobe PDF Title: Zoonotic influenza viruses: antigenic and genetic characteristics and development of candidate vaccine viruses for pandemic preparedness –Virus grippaux zoonotiques: caractéristiques génétiques et antigéniques et mise au point de virus vaccinaux candidats pour se préparer à une pandémie Authors: Issue Date: 20-Oct-2017 Publisher: World Health

WHO2017

38. Influenza vaccines for preventing acute otitis media in infants and children.

Influenza vaccines for preventing acute otitis media in infants and children. BACKGROUND: Acute otitis media (AOM) is one of the most common infectious diseases in children. It has been reported that 64% of infants have an episode of AOM by the age of six months and 86% by one year. Although most cases of AOM are due to bacterial infection, it is commonly triggered by a viral infection. In most children AOM is self limiting, but it does carry a risk of complications. Since antibiotic treatment (...) increases the risk of antibiotic resistance, influenza vaccines might be an effective way of reducing this risk by preventing the development of AOM. OBJECTIVES: To assess the effectiveness of influenza vaccine in reducing the occurrence of acute otitis media in infants and children. SEARCH METHODS: We searched the Cochrane Central Register of Controlled Trials (CENTRAL), MEDLINE, Embase, CINAHL, LILACS, Web of Science, the WHO International Clinical Trials Registry Platform, and ClinicalTrials.gov (15

Cochrane2017

39. Vaccine recommendations for children and youth for the 2017/2018 influenza season

Vaccine recommendations for children and youth for the 2017/2018 influenza season Vaccine recommendations for children and youth for the 2016/2017 influenza season | Position statements and practice points | Canadian Paediatric Society Protecting and promoting the health and well-being of children and youth CPS Member Login | Who We Are What We Do Get Involved Education/CPD Publications Careers > Share PRACTICE POINT Vaccine recommendations for children and youth for the 2016/2017 influenza (...) season Posted: Nov 1 2016 The Canadian Paediatric Society gives permission to print single copies of this document from our website. For permission to reprint or reproduce multiple copies, please see our . Principal author(s) Dorothy L Moore; Canadian Paediatric Society , Abstract The Canadian Paediatric Society continues to encourage an annual influenza vaccination for ALL children and youth ≥6 months of age. Recommendations from the National Advisory Committee on Immunization for the 2016/2017

Canadian Paediatric Society2017

40. H1N1 Influenza Induced Acute Respiratory Distress Syndrome Rescued by Extracorporeal Membrane Oxygenation: a Case Report

H1N1 Influenza Induced Acute Respiratory Distress Syndrome Rescued by Extracorporeal Membrane Oxygenation: a Case Report 29085792 2018 11 13 2450-131X 5 3 2017 Sep Journal of translational internal medicine J Transl Int Med H1N1 Influenza Induced Acute Respiratory Distress Syndrome Rescued by Extracorporeal Membrane Oxygenation: a Case Report. 182-185 10.1515/jtim-2017-0018 Extracorporeal Membrane Oxygenation (ECMO) is now a recognized revolutionary technology, which has emerged as a life (...) -saving therapeutic option for patients with potentially reversible severe respiratory failure who fail to respond positively with the conventional ventilation therapy. Severe acute respiratory distress syndrome (ARDS) is associated with high morbidity and mortality, and ECMO has been proven to increase the survival rates in these patients by improving the gas exchange and thus preventing the further hypoxia and catecholamine induced multi-organ damage. The authors present a case of H1N1 influenza

Journal of translational internal medicine2017 Full Text: Link to full Text with Trip Pro